UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-33095
Achillion Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
1777 Sentry
Park West, Building 14, Suite 200
Blue Bell, Pennsylvania 19422
(215) 709-3040
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, $0.001 par value per share
(Title of each class of securities covered by this Form)
None
(Title of all other
classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
Please place an
X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
|
|
|
|
|
|
Rule 12g-4(a)(1)
|
|
☒
|
|
|
|
Rule 12g-4(a)(2)
|
|
☐
|
|
|
|
Rule 12h-3(b)(1)(i)
|
|
☒
|
|
|
|
Rule 12h-3(b)(1)(ii)
|
|
☐
|
|
|
|
Rule 15d-6
|
|
☐
|
|
|
|
Rule 15d-22(b)
|
|
☐
|
Approximate number of holders of record as of the certification or notice date: One
Pursuant to the requirements of the Securities Exchange Act of 1934, Achillion Pharmaceuticals, Inc. has caused this certification/notice to
be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
Date: February 7, 2020
|
|
Achillion Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
By:
|
|
/s/ Douglas Barry
|
|
|
|
Name:
|
|
Douglas Barry
|
|
|
|
Title:
|
|
Secretary
|